Myriad Genetics Names Johnathan M. Lancaster as Vice President of Medical Affairs
January 22 2015 - 7:05AM
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Johnathan
M. Lancaster, M.D., Ph.D. has joined the Company as the vice
president of Medical Affairs for Oncology, Myriad Genetic
Laboratories, effective Feb. 9, 2015. In this new role, Dr.
Lancaster will provide medical and scientific leadership across
Myriad's expanding portfolio of molecular and companion diagnostic
products and services for oncology. Dr. Lancaster will report
to Lloyd Sanders, general manager for the Oncology Business Unit at
Myriad Genetic Laboratories.
"We are thrilled to welcome Dr. Lancaster to the Myriad team
with his outstanding experience in gynecologic oncology, molecular
genetics and personalized medicine," said Mark Capone, president of
Myriad Genetic Laboratories. "The addition of Dr. Lancaster
continues our commitment to recruit world-class talent and build a
commercial team that is focused on translating our pioneering
science into personalized care for patients. He is joining us
at a pivotal time when we're rapidly expanding our portfolio of
molecular and companion diagnostic tests in oncology."
In his new role, Dr. Lancaster will leverage his molecular
genetics expertise and many years of patient care to enhance the
medical value of Myriad's molecular diagnostic and companion
diagnostic tests in multiple therapeutic areas including lung,
colon, breast and ovarian cancer. Specifically, he will lead
medical and health economic activities to support market access
strategies for the Company's oncology products and professional
education initiatives aimed at improving the practice and
management of healthcare.
"Dr. Lancaster is a recognized healthcare leader and scientist
whose research interests for the last twenty-plus years have
focused on the molecular genetics of women's cancers and the
development of personalized medicine strategies for treatment of
malignancy," said Mr. Sanders. "He has published more than 90
peer-reviewed scholarly articles and multiple book chapters. His
combination of clinical, research and molecular diagnostics
expertise, coupled with his understanding of the business of
medicine and the evolving value-based healthcare environment, is
unique and will be a tremendous asset to our team."
"I am honored and delighted to be joining the Myriad team," said
Dr. Lancaster. "It provides me with a compelling opportunity to
make a difference and accelerate progress in the field of cancer
research and patient care. We share a passion for personalized
medicine, and I look forward to developing innovative and exciting
molecular diagnostic tests that serve the needs of physicians and
enhance care for patients."
Dr. Lancaster comes to Myriad with more than 20 years of
experience in oncology. Over the past 12 years, he held
leadership positions at Moffitt Cancer Center, including president
of Moffitt Medical Group, deputy physician-in-chief, director of
the Center for Women's Oncology, and chair of the Department of
Women's Oncology. Before Moffitt, Dr. Lancaster was a medical
director of the Gynecologic Dysplasia Clinic at Duke University
Medical Center in Durham, NC, where he also completed his residency
and fellowship training. He is board certified in both
obstetrics and gynecology and gynecologic oncology. Dr.
Lancaster received his medical and doctoral degrees in molecular
genetics from the University of Wales, UK.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company
dedicated to making a difference in patients' lives through the
discovery and commercialization of transformative tests to assess a
person's risk of developing disease, guide treatment decisions and
assess risk of disease progression and recurrence. Myriad is
focused on strategic directives to grow existing markets, diversify
through the introduction of new products, including companion
diagnostics, as well as to expand internationally. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung
Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are trademarks
or registered trademarks of Myriad Genetics, Inc. in the United
States and foreign countries. MYGN-F, MYGN-G
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements related to the hiring of Dr. Johnathan
M. Lancaster and the scope of his employment responsibilities; and
the Company's strategic directives under the caption "About Myriad
Genetics." These risks and uncertainties include, but are not
limited to: the risk that sales and profit margins of our molecular
diagnostic tests and pharmaceutical and clinical services may
decline or will not continue to increase at historical rates; risks
related to our ability to transition from our existing product
portfolio to our new tests, including unexpected costs and delays;
risks related to changes in the governmental or private insurers
reimbursement levels for our tests or our ability to obtain
reimbursement for our new tests at comparable levels to our
existing tests; risks related to increased competition and the
development of new competing tests and services; the risk that we
may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and pharmaceutical and
clinical services in a timely manner, or at all; the risk that we
may not successfully develop new markets for our molecular
diagnostic tests and pharmaceutical and clinical services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and pharmaceutical and clinical
services and any future tests and services are terminated or cannot
be maintained on satisfactory terms; risks related to delays or
other problems with operating our laboratory testing facilities;
risks related to public concern over our genetic testing in general
or our tests in particular; risks related to regulatory
requirements or enforcement in the United States and foreign
countries and changes in the structure of the healthcare system or
healthcare payment systems; risks related to our ability to obtain
new corporate collaborations or licenses and acquire new
technologies or businesses on satisfactory terms, if at all; risks
related to our ability to successfully integrate and derive
benefits from any technologies or businesses that we license or
acquire; risks related to our projections about our business,
results of operations and financial condition; risks related to the
potential market opportunity for our products and services; the
risk that we or our licensors may be unable to protect or that
third parties will infringe the proprietary technologies underlying
our tests; the risk of patent-infringement claims or challenges to
the validity of our patents or other intellectual property; risks
related to changes in intellectual property laws covering our
molecular diagnostic tests and pharmaceutical and clinical services
and patents or enforcement in the United States and foreign
countries, such as the Supreme Court decision in the lawsuit
brought against us by the Association for Molecular Pathology et
al; risks of new, changing and competitive technologies and
regulations in the United States and internationally; and other
factors discussed under the heading "Risk Factors" contained in
Item 1A of our Annual Report on Form 10-K for the fiscal year ended
June 30, 2014, which has been filed with the Securities and
Exchange Commission, as well as any updates to those risk factors
filed from time to time in our Quarterly Reports on Form 10-Q or
Current Reports on Form 8-K.
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024